InvestorsHub Logo
Followers 88
Posts 8196
Boards Moderated 0
Alias Born 06/17/2013

Re: None

Monday, 05/01/2017 3:53:51 PM

Monday, May 01, 2017 3:53:51 PM

Post# of 64314
Dr. Ichim and Biorasi

“It is a pleasure to work with the team at Emvolio on clinical translation of this exciting immunotherapeutic approach to cancer,” said Boris Reznik, Chairman and CEO of Biorasi, Inc. “As a Contract Research Organization (CRO) that loves to assist promising companies operating in the area of the Cutting Edge of Medicine, we are pleased that our collaboration has culminated into this regulatory filing.”

(From PR 4/12/17)

http://www.marketwired.com/press-release/therapeutic-solutions-internationals-subsidiary-emvolio-inc-files-investigational-new-otc-pink-tsoi-2209423.htm

Dr. Ichim is a seasoned biotechnology entrepreneur with a track record of scientific excellence. He has founded/co-founded several companies including Batu Biologics, Inc., Medvax Pharma Corp, ToleroTech Inc, bioRASI, and OncoMune LLC. To date he has published over 100 peer-reviewed articles and is co-editor of the textbooks RNA Interference: From Bench to Clinical Translation and Immuno-Oncology Text Book.

(From today's PR 5/1/17)

http://www.marketwired.com/press-release/therapeutic-solutions-international-announces-appointment-dr-thomas-e-ichim-its-subsidiary-otc-pink-tsoi-2213091.htm

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TSOI News